Skip to main content

Table 3 Multivariable Cox regression analysis modelling the independent effect of additional bevacizumab on the risk of death, adjusted for all factors listed

From: Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

  Total study population Propensity score matched sample
(N = 361) (N = 60)
  HR 95 % CI P-value HR 95 % CI P-value
Age (years)       
  < 60 Ref    Ref   
 60–74 1.0 0.76–1.38 0.86 1.8 1.82–4.13 0.15
  ≥ 75 1.3 0.87–1.90 0.21 0.8 0.20–3.53 0.80
Comorbidity       
 No Ref    Ref   
 1 comorbid condition 0.9 0.69–1.22 0.56 1.1 0.40–2.86 0.88
  ≥ 2 comorbid conditions 0.8 0.54–1.04 0.08 1.0 0.34–3.01 1.07
 Unknown 0.7 0.47–1.17 0.19 0.6 0.21–1.98 1.00
Primary tumor localization       
 Rectum Ref    Ref   
 Colon 1.3 1.01–1.65 <0.05 0.6 0.21–1.98 0.35
Adjuvant chemotherapy       
 No Ref    Ref   
 Yes 1.0 0.82–1.34 0.68 1.0 0.44–2.32 0.97
Time to metastases (years)       
  < 1 year Ref    Ref   
 1–2 years 1.1 0.87–1.57 0.28 0.7 0.25–1.87 0.46
  ≥ 2 years 1.0 0.72–1.31 0.85 0.4 0.16–1.22 0.11
Period of diagnosis metastasis       
 2005–2006 Ref    Ref   
 2007–2008 1.1 0.81–1.64 0.42 2.3 0.64–8.34 0.20
 2009–2011 1.1 0.78–1.71 0.47 2.5 0.67–9.62 0.16
Number of organs affected       
 1 organ Ref    Ref   
 2 organs 1.2 0.96–1.63 0.19 1.8 0.74–4.78 0.18
  ≥ 3 organs 1.6 1.12–2.21 <0.01 4.3 1.48–13.00 <0.01
First-line chemotherapy       
 Single agent chemotherapy Ref    Ref   
 Combination chemotherapy 0.9 0.69–1.27 0.69 0.2 0.07–0.49 <0.001
Additional bevacizumab       
 No Ref      
 Yes 0.6 0.49–0.89 <0.01 0.3 0.14–0.79 <0.05
Number of systemic lines       
 1 line Ref      
 2 lines 0.6 0.44–0.84 <0.01 0.5 0.16–1.74 0.29
  ≥ 3 lines 0.4 0.31–0.58 <0.0001 0.3 0.13–0.72 <0.01
  1. N number of patients, HR hazard ratio, CI confidence interval
  2. Bold data; P-value <0.05